Drug Profile
Ompenaclid - Inspirna
Alternative Names: RGX-202; RGX-202-01Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Rgenix
- Developer Inspirna
- Class Antineoplastics; Guanidines; Propionic acids; Small molecules
- Mechanism of Action Creatine transporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Colorectal cancer
- Phase I Biliary cancer; Gastric cancer; Intestinal cancer; Oesophageal cancer; Pancreatic cancer